ΔNp63, CK5/6, TTF-1 and napsin a, a reliable panel to subtype non-small cell lung cancer in biopsy specimens

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 7, 2014, Pages 4247-4253

  Zhao, Wei ^a   Wang, Hui ^a   Peng, Yan ^a   Tian, Bo ^a   Peng, Lei ^a   Zhang, Da Chuan ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Biopsy; Immunohistochemistry; Non small cell lung carcinoma; Squamous cell carcinoma

Indexed keywords

ASPARTIC PROTEINASE; CYTOKERATIN 5; DNA BINDING PROTEIN; NAPSA PROTEIN, HUMAN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TTF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ALGORITHM; BIOPSY; BIOSYNTHESIS; CLASSIFICATION; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; ASPARTIC ACID ENDOPEPTIDASES; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; HUMANS; KERATIN-5; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84906276058     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Burnett RA, Swanson Beck J, Howatson SR, Lee FD, Lessells AM, McLaren KM, Ogston S, Robertson AJ, Simpson JG, Smith GD, et al. Observer variability in histopathological reporting of malignant bronchial biopsy specimens. J Clin Pathol 1994; 47: 711-713.
2. Rivera MP, Detterbeck F and Mehta AC. Dianosis of lung cancer: the guidelines. Chest 2003; 123: 129S-136S.
3. Schreiber G and McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003; 123: 115S-128S.
4. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L and Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008; 3: 1468-1481.
5. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E and Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
6. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D and Giaccone G. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
7. Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, Qaqish BF, Hayward MC, Cabanski CR, Yin X, Socinski MA, Stinchcombe TE, Thorne LB, Allen TC, Banks PM, Beasley MB, Borczuk AC, Cagle PT, Christensen R, Colby TV, Deblois GG, Elmberger G, Graziano P, Hart CF, Jones KD, Maia DM, Miller CR, Nance KV, Travis WD and Funkhouser WK. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med 2013; 137: 32-40.
8. Rosai J. Why microscopy will remain a cornerstone of surgical pathology. Lab Invest 2007; 87: 403-408.
9. Carvalho L. Reclassifying bronchial-pulmonary carcinoma: differentiating histological type in biopsies by immunohistochemistry. Rev Port Pneumol 2009; 15: 1101-1119.
10. Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR and Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000; 53: 537-540.
11. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
12. Candi E, Cipollone R, Cervo DVRP, Gonfloni S, Melino G and Knight R. p63 in epithelial development. Cell Mol Life Sci 2008; 65: 3126-3133.
13. Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB and Grimes HL. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-247.
14. Jorda M, Gomez-Fernandez C, Garcia M, Mousavi F, Walker G, Mejias A, Fernandez-Castro G and Ganjei-Azar P. P63 differentiates sub types of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer 2009; 117: 46-50.
15. Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P and Baloch Z. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009; 37: 178-183.
16. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 2012; 36: 895-899.
17. Righi L, Graziano P, Fornari A, Rossi G, Barbareschi M, Cavazza A, Pelosi G, Scagliotti GV and Papotti M. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011; 117: 3416-3423.
18. Camilo R, Capelozzi VL, Siqueira SA and Bernardi DCF. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 2006; 37: 542-546.
19. Downey P, Cummins R, Moran M and Gulmann C. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008; 116: 526-529.
20. Loo PS, Thomas SC, Nicolson MC, Fyfe MN and Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5: 442-447.
21. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A and Popat S. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010; 5: 436-441.
22. Viberti L, Bongiovanni M, Croce S and Bussolati G. 34betaE12 Cytokeratin Immunodetection in the Differential Diagnosis of Small Cell Tumors of Lung. Int J Surg Pathol 2000; 8: 317-322.
23. Kargi A, Gurel D and Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15: 415-420.
24. Nakamura N, Miyagi E, Murata S, Kawaoi A and Katoh R. Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues. Mod Pathol 2002; 15: 1058-1067.
25. Yang M and Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-661.
26. Bishop JA, Sharma R and Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20-25.
27. Suzuki A, Shijubo N, Yamada G, Ichimiya S, Satoh M, Abe S and Sato N. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005; 201: 579-586.
28. Hirano T, Gong Y, Yoshida K, Kato Y, Yashima K, Maeda M, Nakagawa A, Fujioka K, Ohira T, Ikeda N, Ebihara Y, Auer G and Kato H. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41: 155-162.
29. Pardo J, Martinez-Penuela AM, Sola JJ, Panizo A, Gurpide A, Martinez-Penuela JM and Lozano MD. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol 2009; 17: 383-392.
30. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN and Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11: 3766-3772.
31. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004; 8: 259-267.